logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Calcineurin Inhibitor Immunosuppressant class drugs

    FiltersReset Filters
    6 results

    • cequa

      (cyclosporine)
      Sun Pharmaceutical Industries, Inc.
      Usage: CEQUA ophthalmic solution is indicated for increasing tear production in patients with keratoconjunctivitis sicca (dry eye) as a calcineurin inhibitor immunosuppressant.

    • cyclosporine

      (CYCLOSPORINE)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Cyclosporine capsules (modified) are indicated for preventing organ rejection in kidney, liver, and heart transplants. They also treat severe rheumatoid arthritis inadequately responding to methotrexate and manage severe, recalcitrant plaque psoriasis in nonimmunocompromised adults who have not responded to other systemic therapies.

    • lupkynis

      (Voclosporin)
      Aurinia Pharma U.S., Inc.
      Usage: LUPKYNIS is indicated for the treatment of adult patients with active lupus nephritis (LN) in combination with a background immunosuppressive therapy. Its safety and efficacy have not been established with cyclophosphamide, and its use in this context is not recommended.

    • neoral

      (cyclosporine)
      Novartis Pharmaceuticals Corporation
      Usage: Neoral is indicated for the prophylaxis of organ rejection in kidney, liver, and heart transplants, treatment of severe active rheumatoid arthritis unresponsive to methotrexate, and treatment of severe plaque psoriasis in adults who have not responded to other systemic therapies.

    • restasis

      (cyclosporine)
      Allergan, Inc.
      Usage: RESTASIS® ophthalmic emulsion is indicated for increasing tear production in patients with keratoconjunctivitis sicca, whose tear production is likely suppressed due to ocular inflammation. It is not effective in patients currently using topical anti-inflammatory drugs or punctal plugs.

    • sandimmune

      (cyclosporine)
      Novartis Pharmaceuticals Corporation
      Usage: Sandimmune (cyclosporine) is indicated for preventing organ rejection in kidney, liver, and heart transplants, to be used with adrenal corticosteroids. It may also treat chronic rejection in patients previously on other immunosuppressants. Injection form is reserved for patients who cannot take oral formulations due to anaphylaxis risk.